Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Borg

Showing results (111-120 of 224) with videos related to

Pageof 23
Sort By:
Clinical Colorectal Cancer|October 23, 2012
Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancerErion Dobi, Franck Monnien, Stefano Kim, et al.
BMC Gastroenterology|August 14, 2014
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapyFrédéric Fiteni, Marine Jary, Franck Monnien, et al.
Journal for Immunotherapy of Cancer|November 24, 2020
Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastasesMarie Kroemer, Celia Turco, Laurie Spehner, et al.
BMC Cancer|December 31, 2013
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levelsStefano Kim, Erion Dobi, Marine Jary, et al.
Cell Death & Disease|March 1, 2019
EMT is associated with an epigenetic signature of ECM remodeling genesPaul Peixoto, Amandine Etcheverry, Marc Aubry, et al.
International Journal of Cancer|August 10, 2019
CD4 T cells target colorectal cancer antigens upregulated by oxaliplatinJeanne Galaine, Célia Turco, Charline Vauchy, et al.
Cancer Research Communications|January 14, 2025
Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT TrialsAngélique Vienot, Dewi Vernerey, Adeline Bouard, et al.
Annals of Surgical Oncology|January 15, 2014
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resectionFrancois Ghiringhelli, Damien Bichard, Samuel Limat, et al.
Frontiers in Oncology|October 31, 2022
Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trialAlice Debernardi, Aurélia Meurisse, Jean-Luc Prétet, et al.
Clinical Nutrition (Edinburgh, Scotland)|March 14, 2020
Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancerAdeline Dolly, Thierry Lecomte, Olivier Bouché, et al.
Pageof 23

Showing results (111-120 of 224) with videos related to

Sort By:
Pageof 23
Clinical Colorectal Cancer|October 23, 2012
Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancerErion Dobi, Franck Monnien, Stefano Kim, et al.
BMC Gastroenterology|August 14, 2014
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapyFrédéric Fiteni, Marine Jary, Franck Monnien, et al.
Journal for Immunotherapy of Cancer|November 24, 2020
Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastasesMarie Kroemer, Celia Turco, Laurie Spehner, et al.
BMC Cancer|December 31, 2013
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levelsStefano Kim, Erion Dobi, Marine Jary, et al.
Cell Death & Disease|March 1, 2019
EMT is associated with an epigenetic signature of ECM remodeling genesPaul Peixoto, Amandine Etcheverry, Marc Aubry, et al.
International Journal of Cancer|August 10, 2019
CD4 T cells target colorectal cancer antigens upregulated by oxaliplatinJeanne Galaine, Célia Turco, Charline Vauchy, et al.
Cancer Research Communications|January 14, 2025
Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT TrialsAngélique Vienot, Dewi Vernerey, Adeline Bouard, et al.
Annals of Surgical Oncology|January 15, 2014
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resectionFrancois Ghiringhelli, Damien Bichard, Samuel Limat, et al.
Frontiers in Oncology|October 31, 2022
Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trialAlice Debernardi, Aurélia Meurisse, Jean-Luc Prétet, et al.
Clinical Nutrition (Edinburgh, Scotland)|March 14, 2020
Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancerAdeline Dolly, Thierry Lecomte, Olivier Bouché, et al.
Pageof 23